| 7.08 0.22 (3.21%) | 08-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.18 | 1-year : | 10.72 |
| Resists | First : | 7.86 | Second : | 9.18 |
| Pivot price | 6.8  |
|||
| Supports | First : | 6.42 | Second : | 5.53 |
| MAs | MA(5) : | 6.99  |
MA(20) : | 6.57 |
| MA(100) : | 5.3 |
MA(250) : | 6.83 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 58.5 |
D(3) : | 59 |
| RSI | RSI(14): 62 |
|||
| 52-week | High : | 11.25 | Low : | 3.43 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VSTM ] has closed below upper band by 33.9%. Bollinger Bands are 8.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.2 - 7.25 | 7.25 - 7.29 |
| Low: | 6.84 - 6.89 | 6.89 - 6.93 |
| Close: | 7.01 - 7.09 | 7.09 - 7.16 |
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Sun, 23 Aug 2026
Enterprise value to revenue forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Sun, 16 Aug 2026
Precision Trading with Verastem Inc. (VSTM) Risk Zones - Stock Traders Daily
Fri, 14 Aug 2026
Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital - Stock Titan
Thu, 30 Jul 2026
BlackRock, Inc. (VSTM) discloses 6.19M INC shares, or 7.0% ownership, in 13G/A - Stock Titan
Thu, 23 Jul 2026
Verastem Inc. (VSTM) holder outlines potential sale of 31,924 common shares - Stock Titan
Wed, 15 Jul 2026
RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 7.057e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 24,140 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5865e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -231.6 % |
| Operating Margin | -81.7 % |
| Return on Assets (ttm) | -49.6 % |
| Return on Equity (ttm) | -471.2 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 2673.79 |
| Sales Per Share | 3.01828e+008 |
| EBITDA (p.s.) | 2.64517e+008 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -162 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.2 |
| Dividend | 0 |
| Forward Dividend | 1.983e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|